DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Gevokizumab
Gevokizumab
Old and New Challenges in Uveitis Associated with Behçet's Disease
Review Anti-Cytokine Biologic Treatment Beyond Anti-TNF in Behçet's Disease
New Biological Therapies: Introduction to the Basis of the Risk of Infection
Clinical Research in Adult Vasculitis
Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
An Update on the Use of Biologic Therapies in the Management of Uveitis in Behçet’S Disease: a Comprehensive Review Thomas W
The Two Tontti Tudiul Lui Hi Ha Unit
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Gevokizumab for Chronic Non-Infectious Uveitis
(INN) for Biological and Biotechnological Substances
WO 2018/234879 Al 27 December 2018 (27.12.2018) W !P O PCT
INN Working Document 05.179 Update 2011
Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
Therapeutic Antibody
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Noninfectious Uveitis Open Access to Scientific and Medical Research DOI
Wo 2016/061562 A2 ©
Recent Biotherapies and Infections
Top View
(INN) for Biological and Biotechnological Substances
CJM112 a Randomized, Subject and Investigator Blinded, Placebo
WO 2018/013551 Al 18 January 2018 (18.01.2018) W !P O PCT
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
2019-05-Meet-Novartis-Management-Presentation.Pdf
Journal for Immunotherapy of Cancer (JITC) Preprint
Antibody Modeling
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
(12) Patent Application Publication (10) Pub. No.: US 2015/0166649 A1 Ariaans Et Al
Optimising Drug Therapy for Non-Infectious Uveitis
Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis
Vaccination in Immunosuppressed Adults ASID Adult Immunisation Workshop 9 May 2018
Antibody-Drug Analogues
Current Perspectives on the Role of Interleukin-1 Signaling in the Pathogenesis of Asthma and COPD
Kinase Inhibition in Autoimmunity and Inflammation
CV Blauvelt 1219
Bjophthalmol-2020-315935 1045..1051
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
(INN) for Biological and Biotechnological Substances
Bjophthalmol-2020-315935 1..2
A Review of Biologics for Uveitis Treatment of Uveitis with These Agents Is Increasingly Promising
Rheumatoid Arthritis Associated Episcleritis and Scleritis: an Update on Treatment Perspectives
CV Blauvelt March 2021
Cytokine Targeting in Rheumatoid Arthritis T ⁎ Viet L
Compounds and Methods for Treating Inflammatory
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Effectiveness of Pharmacological Agents for the Treatment of Non-Infectious Scleritis: a Systematic Review Protocol Sathana Ingaralingam1, Saaeha Rauz1, Philip I
WO 2015/105926 Al 16 July 2015 (16.07.2015) P O PCT
Pyoderma Gangrenosum – a Guide to Diagnosis and Management
Gevokizumab in the Treatment of Autoimmune Non-Necrotizing Anterior Scleritis: Results of a Phase I/II Clinical Trial
Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016